Article Sidebar
Published:
Aug 28, 2013Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Prescribing Practices and Cost of Drugs for Peptic Ulcer in a Primary Health Center in Pulau Penang, Malaysia
Abstract
Purpose: Description of the prescribing patterns of gastric acid suppressant treatment in peptic ulcer disease and the cost analysis in a tertiary health center in Malaysia
Methods: A cross sectional retrospective study was conducted at a Universiti Sans Malaysia (USM) Health Center, Clinic, Malaysia. Convenience sampling was used to include 100 peptic ulcer patients.
Results: Sixty three percent of the patients were male and 37 % female. The majority of the patients were Malay (71 %) and mean age was 46 ± 9.7 years. The most frequently prescribed monotherapy antiulcer drugs were ranitidine (83 %) and omeprazole (17 %), while for combination therapy (with antacids), it was ranitidine (85 %). The average cost of anti-ulcer drug therapy was 15.54 Ringgit Malaysian (RM), i.e., (USD 4.98) for omeprazole and RM 4.62 (USD 1.48) for ranitidine.
Conclusion: The practitioners in this study preferred to prescribe ranitidine much more frequently than omeprazole. Considering the cost burden of proton pump inhibitors (PPIs) and their relatively more adverse effects, this may be a cost-effective strategy, but the benefits of ranitidine in terms of therapeutic efficacy need to be ascertained.
Keywords: Peptic ulcer, Gastric acid suppressant, H2 receptor antagonist, Proton pump inhibitor
